

Wouter Rl Hendrickx

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6056230/publications.pdf>

Version: 2024-02-01

50
papers

2,078
citations

304743

22
h-index

265206

42
g-index

55
all docs

55
docs citations

55
times ranked

3926
citing authors

#	ARTICLE	IF	CITATIONS
1	Graphene oxide activates B cells with upregulation of granzyme B expression: evidence at the single-cell level for its immune-modulatory properties and anticancer activity. <i>Nanoscale</i> , 2022, 14, 333-349.	5.6	9
2	Transcriptomic profile investigations highlight a putative role for NUDT16 in sepsis. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1714-1721.	3.6	5
3	A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. <i>British Journal of Cancer</i> , 2021, 124, 760-769.	6.4	13
4	BloodGen3Module: blood transcriptional module repertoire analysis and visualization using R. <i>Bioinformatics</i> , 2021, 37, 2382-2389.	4.1	18
5	Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry. <i>Npj Breast Cancer</i> , 2021, 7, 10.	5.2	11
6	Germline genetic contribution to the immune landscape of cancer. <i>Immunity</i> , 2021, 54, 367-386.e8.	14.3	95
7	Network-based identification of key master regulators associated with an immune-silent cancer phenotype. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	11
8	Myeloid Cells Are Enriched in Tonsillar Crypts, Providing Insight into the Viral Tropism of Human Papillomavirus. <i>American Journal of Pathology</i> , 2021, 191, 1774-1786.	3.8	7
9	Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10376-10388.	3.6	13
10	Annexin A3 in sepsis: novel perspectives from an exploration of public transcriptome data. <i>Immunology</i> , 2020, 161, 291-302.	4.4	32
11	Expression of NK cell receptor ligands in primary colorectal cancer tissue in relation to the phenotype of circulating NK- and NKT cells, and clinical outcome. <i>Molecular Immunology</i> , 2020, 128, 205-218.	2.2	15
12	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
13	HLA-G: A New Immune Checkpoint in Cancer?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4528.	4.1	52
14	Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. <i>Frontiers in Immunology</i> , 2019, 10, 2410.	4.8	33
15	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. <i>Scientific Reports</i> , 2019, 9, 8572.	3.3	36
16	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 1383-1391.	6.4	54
17	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
18	NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. <i>Frontiers in Immunology</i> , 2018, 9, 947.	4.8	261

#	ARTICLE	IF	CITATIONS
19	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncolmmunology</i> , 2017, 6, e1253654.	4.6	146
20	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. <i>Oncolmmunology</i> , 2017, 6, e1323618.	4.6	42
21	Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells. <i>Nature Communications</i> , 2017, 8, 1109.	12.8	111
22	Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2229.	4.1	105
23	The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 429-445.	2.6	45
24	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	1.6	14
25	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	1.6	14
26	Disentangling the relationship between tumor genetic programs and immune responsiveness. <i>Current Opinion in Immunology</i> , 2016, 39, 150-158.	5.5	57
27	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. <i>Cancer Immunology Research</i> , 2016, 4, 600-610.	3.4	86
28	Defining genetic modulators of intratumoral immune response in breast cancer through a system biology approach. , 2016, , .		0
29	Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?. , 2015, 3, P381.		0
30	Toward the identification of genetic determinants of breast cancer immune responsiveness. , 2015, 3, P1.		4
31	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, , 99-127.	0.4	4
32	Prognostic and predictive immune gene signatures in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 433-444.	2.4	75
33	Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice. <i>Breast Cancer Research</i> , 2015, 17, 38.	5.0	35
34	Selenium Biomarkers in Prostate Cancer Cell Lines and Influence of Selenium on Invasive Potential of PC3 Cells. <i>Frontiers in Oncology</i> , 2013, 3, 239.	2.8	13
35	Short-Term Prognostic Index for Breast Cancer: NPI or Lpi. <i>Pathology Research International</i> , 2011, 2011, 1-7.	1.4	4
36	Relationship Between Age and Axillary Lymph Node Involvement in Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2931-2937.	1.6	72

#	ARTICLE	IF	CITATIONS
37	Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Research and Treatment, 2009, 115, 349-358.	2.5	18
38	Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Research and Treatment, 2009, 113, 181-187.	2.5	76
39	Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. Breast Cancer Research and Treatment, 2008, 110, 153-159.	2.5	11
40	Plasma MMP1 and MMP8 expression in breast cancer: Protective role of MMP8 against lymph node metastasis. BMC Cancer, 2008, 8, 77.	2.6	55
41	Association of MMP8 gene variation with breast cancer prognosis. Breast Cancer Research, 2008, 10, .	5.0	2
42	Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis. Breast Cancer Research, 2008, 10, .	5.0	2
43	Clinicopathological Features of Inflammatory versus Noninflammatory Locally Advanced Nonmetastatic Breast Cancer. Tumor Biology, 2008, 29, 211-216.	1.8	10
44	Does Estrogen Receptorâ€“Negative/Progesterone Receptorâ€“Positive Breast Carcinoma Exist?. Journal of Clinical Oncology, 2008, 26, 335-336.	1.6	91
45	In Early-Stage Breast Cancer, the Estrogen Receptor Interacts With Correlation Between Human Epidermal Growth Factor Receptor 2 Status and Age at Diagnosis, Tumor Grade, and Lymph Node Involvement. Journal of Clinical Oncology, 2008, 26, 1768-1769.	1.6	4
46	Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. International Journal of Biological Markers, 2008, 23, 161-168.	1.8	36
47	Association of <i>Matrix Metalloproteinase-8</i> Gene Variation with Breast Cancer Prognosis. Cancer Research, 2007, 67, 10214-10221.	0.9	85
48	Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas. Disease Markers, 2007, 23, 189-196.	1.3	19
49	Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Breast Cancer Research and Treatment, 2007, 106, 127-133.	2.5	19
50	Plasma Gelatinase Levels in Patients with Primary Breast Cancer in Relation to Axillary Lymph Node Status, Her2/neu Expression and other Clinicopathological Variables. Clinical and Experimental Metastasis, 2005, 22, 495-502.	3.3	17